Aarti Drugs Limited (AARTIDRUGS.BO)
INR 330.65
(2.85%)
INR 330.65
(2.85%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.24 Billion INR | 2.82% |
| 2022 | 3.11 Billion INR | -10.12% |
| 2021 | 3.43 Billion INR | -22.61% |
| 2020 | 4.45 Billion INR | 65.63% |
| 2019 | 2.71 Billion INR | 27.19% |
| 2018 | 2.17 Billion INR | 4.42% |
| 2017 | 2.02 Billion INR | 5.29% |
| 2016 | 1.94 Billion INR | 7.47% |
| 2015 | 1.79 Billion INR | 4.17% |
| 2014 | 1.69 Billion INR | 14.81% |
| 2013 | 1.46 Billion INR | 22.48% |
| 2012 | 1.2 Billion INR | 50.04% |
| 2011 | 791.07 Million INR | 12.96% |
| 2010 | 626.91 Million INR | -16.52% |
| 2009 | 857.71 Million INR | 25.44% |
| 2008 | 683.75 Million INR | 37.95% |
| 2007 | 495.63 Million INR | 10.87% |
| 2006 | 447.02 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 685.3 Million INR | 3.74% |
| 2024 Q1 | 649.5 Million INR | -23.97% |
| 2023 Q4 | 858.1 Million INR | 19.5% |
| 2023 Q2 | 771.3 Million INR | -8.91% |
| 2023 FY | - INR | 2.82% |
| 2023 Q1 | 846.7 Million INR | -10.32% |
| 2023 Q3 | 718.1 Million INR | -6.9% |
| 2022 FY | - INR | -10.12% |
| 2022 Q4 | 944.1 Million INR | 31.75% |
| 2022 Q2 | 743.2 Million INR | 10.27% |
| 2022 Q1 | 674 Million INR | -25.64% |
| 2022 Q3 | 716.6 Million INR | -3.58% |
| 2021 FY | - INR | -22.61% |
| 2021 Q4 | 906.38 Million INR | -6.23% |
| 2021 Q3 | 966.6 Million INR | 30.94% |
| 2021 Q1 | 813.1 Million INR | -1.72% |
| 2021 Q2 | 738.2 Million INR | -9.21% |
| 2020 Q4 | 827.36 Million INR | -23.23% |
| 2020 Q1 | 1.35 Billion INR | 77.59% |
| 2020 Q2 | 1.16 Billion INR | -13.68% |
| 2020 Q3 | 1.07 Billion INR | -7.68% |
| 2020 FY | - INR | 65.63% |
| 2019 Q3 | 677.4 Million INR | -1.11% |
| 2019 Q4 | 761.47 Million INR | 12.41% |
| 2019 FY | - INR | 27.19% |
| 2019 Q2 | 685 Million INR | 25.07% |
| 2019 Q1 | 547.7 Million INR | -4.56% |
| 2018 FY | - INR | 4.42% |
| 2018 Q3 | 520.3 Million INR | 10.49% |
| 2018 Q1 | 535.3 Million INR | -6.71% |
| 2018 Q4 | 573.89 Million INR | 10.3% |
| 2018 Q2 | 470.9 Million INR | -12.03% |
| 2017 FY | - INR | 5.29% |
| 2017 Q4 | 573.8 Million INR | 6.14% |
| 2017 Q3 | 540.6 Million INR | 2.74% |
| 2017 Q2 | 526.2 Million INR | 48.35% |
| 2017 Q1 | 354.7 Million INR | -25.01% |
| 2016 Q1 | 481.3 Million INR | 5.2% |
| 2016 Q4 | 473 Million INR | 9.69% |
| 2016 FY | - INR | 7.47% |
| 2016 Q2 | 511.4 Million INR | 6.25% |
| 2016 Q3 | 431.2 Million INR | -15.68% |
| 2015 Q2 | 425.6 Million INR | -2.18% |
| 2015 Q4 | 457.5 Million INR | 6.03% |
| 2015 Q3 | 431.5 Million INR | 1.39% |
| 2015 Q1 | 435.1 Million INR | 1.28% |
| 2015 FY | - INR | 4.17% |
| 2014 Q2 | 424.2 Million INR | 6.45% |
| 2014 Q4 | 429.61 Million INR | -3.3% |
| 2014 FY | - INR | 14.81% |
| 2014 Q3 | 444.3 Million INR | 4.74% |
| 2014 Q1 | 398.5 Million INR | -11.35% |
| 2013 Q2 | 352.1 Million INR | 13.8% |
| 2013 Q3 | 374.4 Million INR | 6.33% |
| 2013 Q4 | 449.5 Million INR | 20.06% |
| 2013 FY | - INR | 22.48% |
| 2013 Q1 | 309.4 Million INR | -11.04% |
| 2012 FY | - INR | 50.04% |
| 2012 Q1 | 603.7 Million INR | 0.0% |
| 2012 Q2 | 295.7 Million INR | -51.02% |
| 2012 Q3 | 297.7 Million INR | 0.68% |
| 2012 Q4 | 347.77 Million INR | 16.82% |
| 2011 FY | - INR | 12.96% |
| 2010 FY | - INR | -16.52% |
| 2009 FY | - INR | 25.44% |
| 2008 FY | - INR | 37.95% |
| 2007 FY | - INR | 10.87% |
| 2006 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 66.219% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 94.742% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 52.664% |
| Granules India Limited | 8.6 Billion INR | 62.242% |
| Indoco Remedies Limited | 2.64 Billion INR | -22.726% |
| Achyut Healthcare Limited | 524 Thousand INR | -619867.557% |
| Ajanta Pharma Limited | 12.56 Billion INR | 74.146% |
| Alkem Laboratories Limited | 24.19 Billion INR | 86.573% |
| Alpa Laboratories Limited | 86.12 Million INR | -3671.907% |
| Brooks Laboratories Limited | 41.72 Million INR | -7685.252% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -37.841% |
| Bajaj HealthCare Limited | 444.51 Million INR | -630.824% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -119.646% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 96.32% |
| Eris Lifesciences Limited | 6.98 Billion INR | 53.501% |
| FDC Limited | 4.4 Billion INR | 26.196% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 71.362% |
| Gufic Biosciences Limited | 1.48 Billion INR | -119.43% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 52.655% |
| Ipca Laboratories Limited | 13.29 Billion INR | 75.573% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -904.337% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 4026.928% |
| Lasa Supergenerics Limited | -65.08 Million INR | 5091.749% |
| Laurus Labs Limited | 8 Billion INR | 59.423% |
| Lupin Limited | 36.96 Billion INR | 91.213% |
| Mankind Pharma Limited | 28.09 Billion INR | 88.437% |
| Medicamen Biotech Limited | 245.66 Million INR | -1222.409% |
| Medico Remedies Limited | 150.37 Million INR | -2060.309% |
| Megasoft Limited | 284.73 Million INR | -1040.947% |
| NATCO Pharma Limited | 18.79 Billion INR | 82.715% |
| Piramal Pharma Limited | 13.05 Billion INR | 75.117% |
| RPG Life Sciences Limited | 1.28 Billion INR | -153.502% |
| Sigachi Industries Limited | 883.39 Million INR | -267.743% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 97.652% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 30.543% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -655.011% |
| Unichem Laboratories Limited | 742.35 Million INR | -337.611% |
| Wanbury Limited | 985.49 Million INR | -229.646% |
| Windlas Biotech Limited | 781.72 Million INR | -315.575% |
| ZIM Laboratories Limited | 462.09 Million INR | -603.019% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 94.222% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 187.065% |
| Divi's Laboratories Limited | 25.43 Billion INR | 87.225% |
| Hester Biosciences Limited | 539.47 Million INR | -502.189% |
| Procter & Gamble Health Limited | 3.01 Billion INR | -7.77% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -375.963% |
| Bal Pharma Limited | 345.59 Million INR | -840.019% |
| Strides Pharma Science Limited | 3.76 Billion INR | 13.708% |
| Venus Remedies Limited | 711.8 Million INR | -356.396% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 16.902% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -107.741% |
| Shilpa Medicare Limited | 2.58 Billion INR | -25.527% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -24.631% |
| Suven Life Sciences Limited | -992.78 Million INR | 427.226% |
| Ind-Swift Limited | 1.06 Billion INR | -205.017% |
| Valiant Laboratories Limited | 12.73 Million INR | -25401.452% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 65.199% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 215.122% |
| Themis Medicare Limited | 562.6 Million INR | -477.424% |
| Hikal Limited | 2.69 Billion INR | -20.667% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 90.721% |
| Sequent Scientific Limited | 549.8 Million INR | -490.875% |
| Novartis India Limited | 1.26 Billion INR | -155.939% |
| Wockhardt Limited | 1.08 Billion INR | -200.799% |
| Jubilant Pharmova Limited | 8 Billion INR | 59.423% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -24770.847% |
| Neuland Laboratories Limited | 4.74 Billion INR | 31.582% |
| Morepen Laboratories Limited | 1.72 Billion INR | -88.222% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -1030.253% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -1756.933% |